Drug
Recombinant Coagulation Factor
Recombinant Coagulation Factor: highest development phase Post-Market, developed by Swedish Orphan Biovitrum. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Swedish Orphan Biovitrum
Trials
| Drug | Phase | Indication |
|---|---|---|
| Recombinant coagulation factor (rFVIIIFc) NCT03103542 | Post-Market | Hemophilia A |
Latest
No recent events.
Follow Recombinant Coagulation Factor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.